What one share of Celularity holds
We are a cellular and regenerative medicine company focused on advancing health longevity and redefining the standard of care for age-related disease using novel therapies derived from the post-partum human placenta. The objective of extending health longevity is to meaningfully reduce the duration and severity in which an individual experiences aging-related degenerative diseases and disorders associated with increased mortality towards the end of life.
Celularity’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.66 |
|---|---|
| Profit | −$1.63 |
| Cash and investments | $0.02 |
| Debt | $1.15 |
| Book value | −$1.21 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $7.75 | −$113.06 | $15.11 | −$49.42 | — | −$286.79 |
| 2021 | $3.18 | −$14.93 | $0.93 | −$17.34 | — | $8.00 |
| 2022 | $1.20 | $0.95 | $0.35 | −$9.55 | — | $13.36 |
| 2023 | $1.28 | −$11.02 | $0.06 | −$2.23 | — | $2.11 |
| 2024 | $2.48 | −$2.64 | $0.01 | −$0.30 | — | $0.39 |
| 2025 | $1.04 | −$3.59 | — | — | — | −$1.32 |
Common questions about Celularity
How much does one share of Celularity earn?
Over the last 12 months, Celularity lost $1.63 for each share on $0.66 of sales.
Does Celularity pay a dividend?
Celularity didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Celularity’s book value per share?
Celularity’s book value is negative (−$1.21 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Celularity have?
Each share of Celularity has $0.02 of cash and investments and $1.15 of debt, as of June 30, 2026.
Has Celularity bought back shares?
Celularity’s share count rose about 1290% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.